Comparative Pharmacology
Head-to-head clinical analysis: MESANTOIN versus PEGANONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MESANTOIN versus PEGANONE.
MESANTOIN vs PEGANONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Anticonvulsant; stabilizes neuronal membranes and decreases seizure propagation by blocking sodium channels and inhibiting voltage-gated calcium channels.
Ethotoin, a hydantoin derivative, stabilizes neuronal membranes by promoting sodium efflux and reducing sodium influx, decreasing post-tetanic potentiation and seizure spread.
300-600 mg orally once daily as extended-release tablet; alternatively, 100-200 mg orally three times daily as immediate-release tablet.
500-1000 mg orally 2 to 4 times daily (maximum 4000 mg/day).
None Documented
None Documented
The terminal elimination half-life is 22 hours (range 7-42 hours) with saturation kinetics; at therapeutic concentrations, half-life may prolong due to dose-dependent metabolism, requiring careful monitoring.
Terminal elimination half-life of ethotoin (PEGANONE) is approximately 5-8 hours in adults; variable due to saturable metabolism. Shorter half-life requires multiple daily dosing to maintain therapeutic levels (therapeutic range 15-50 mcg/mL).
Renal excretion accounts for approximately 60-80% of an administered dose as unchanged drug and metabolites (primarily p-hydroxyphenytoin glucuronide). Biliary/fecal excretion is minor, <5%.
Primarily hepatic metabolism; less than 5% excreted unchanged in urine. Renal elimination of metabolites accounts for ~40-60% of an oral dose; biliary/fecal elimination accounts for ~10-20%.
Category C
Category C
Anticonvulsant (Hydantoin)
Anticonvulsant (Hydantoin)